What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Link
http://link.springer.com/content/pdf/10.1007/s11899-010-0069-3.pdf
Reference88 articles.
1. •• Tam CS and Keating MJ: Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 2010, 7:521–532. This is a thorough review of chemoimmunotherapy in CLL.
2. •• Hallek M, Fischer K, Fingerle-Rowson G, et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164–1174. This publication demonstrates the survival advantage gained by adding rituximab to fludarabine and cyclophosphamide in this important phase III study in untreated patients with CLL. In addition, the study confirms the inferior response and outcomes experienced by patients with 17p deletions.
3. • Tam CS, O’Brien S, Wierda W, et al.: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975–980. This article reports long-term results of the initial study of frontline FCR in patients with CLL.
4. Isobe M, Emanuel BS, Givol D, et al.: Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986, 320:84–85.
5. Hollstein M, Sidransky D, Vogelstein B, et al.: p53 mutations in human cancers. Science 1991, 253:49–53.
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Management of atypical chronic lymphocytic leukemia presenting with extreme leukocytosis;Clinical Case Reports;2020-03-05
2. Outcome of chronic lymphocytic leukemia with deletion 17p;Cancer Research, Statistics, and Treatment;2020
3. Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial;Health and Quality of Life Outcomes;2019-11-15
4. TP53 Staining in Tissue Samples of Chronic Lymphocytic Lymphoma Cases: An Immunohistochemical Survey of 51 Cases;Turkish Journal of Hematology;2017-03-01
5. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?;Expert Review of Hematology;2016-06-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3